🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great work Chris Jackson, MD MS Dan Higginson & Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center colleagues Our 3 Fx SBRT dose constraints now incorporates D0.1cc <19.1; we kept D0.03cc<21.9 Gy Mayo Clinic Radiation Oncology

Just in time for #Xmas Vpleased to share 5y of work from #chualabnccs on the mutational landscape of #Radioresistant #Cancers We show that BAHD1-heterochromatin modification dominates for acquired RTresistance Opportunities for new targets! nature.com/articles/s4141…

Congrats Chris Jackson, MD MS Dan Higginson Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center for this important work characterizing dosimetric risk factors for radiation myelitis. Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy jamanetwork.com/journals/jamao…

Very nice (and gigantic) retrospective analysis of personalized CTV design in NPC, also dropping CTV70. PTV70 and PTV60 volume reduction ~50-60% versus historical controls. Absolute marginal failure risk < 1%. redjournal.org/article/S0360-…

Thank you to Drs Katsoulakis and Spratt for your thoughtful commentary on our work Eva Katsoulakis Daniel E Spratt

Cord constraints quadshotnews.com/cord-constrain… QuadShot News thank you for featuring our work Dan Higginson

Here is a recent #MSKKids lecture Memorial Sloan Kettering Cancer Center: Toward a unified theory of why young people develop cancer ☛ alexkentsis.net/lecture-toward…

1/Delighted to announce the newest paper from our lab, “Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage”, is out today in Nature Cell Biology, nature.com/articles/s4155….

Check out our latest work from the spine team Memorial Sloan Kettering Radiation Oncology identifying a new constraint to min risk of myelitis after spine SBRT Dan Higginson

A few years back we published a study on mutant IDH-induced BRCAness conferring PARPi sensitivity in nature w/ Peter Glazer….we then directly translated this into multiple trials, including this one below; Bench-2-bedside at the speed of Yale science! pubmed.ncbi.nlm.nih.gov/32494005/

In patients with locally advanced hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) combined with sorafenib improved progression-free survival and showed a clinically important improvement in overall survival compared to sorafenib alone. ja.ma/4bbMrXr

Our latest lab paper is here! "PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer" nature.com/articles/s4146… rdcu.be/ecaJ4 Nature Communications 1/3

Congrats to Giulia Marvaso prof. Barbara Jereczek-Fossa Piet Ost Chad Tang, MD on the RADIOSA trial, which randomized patients with omHSPC to SBRT vs. SBRT+6 months ADT thelancet.com/journals/lanon…

Proud of my mentor, Dr Chris Crane, who was awarded the Nobility in Science Award by the National Pancreas Foundation earlier tonight. Dr Crane’s work pioneering ablative radiotherapy for pancreatic cancer has been a game changer for the treatment of locally advanced PDAC!

Fantastic talk yesterday by Shankar Siva, a tour de force of SABR for Renal Cell Carcinoma (and clinical trial acronyms)

Congrats to the MSK Rad Onc Class of 2030! Looking forward to working with all of you!

Honored to be nominated by Memorial Sloan Kettering Radiation Oncology to attend my first National Comprehensive Cancer Network (NCCN) Annual Meeting and excited for the Fellows Session in sunny Orlando! Great to have a break from NY cold.

Our secondary analysis of ARST1431 looking at local control with radiotherapy for pediatric rhabdomyosarcoma was published this week in IJROBP - The Red Journal. Thanks to Dr. Suzanne Wolden and the rest of COG Soft Tissue Sarcoma Group for your mentorship. redjournal.org/article/S0360-…

Studying for rad onc clinical boards and doing questions about fallopian tube carcinoma staging like the top-most orangutan

We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué,